Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC70	PIK-93	1	72	sigmoid	sigmoid	HCC70 PIK-93 0 1 72	8	1.442	3.47	0.482	0.137	18.6	-1.0	0.656	0.774	0.0116	NA	10.7	0.649	0.904	10.7	0.0	0.632	0.746	0.0163	NA
BT-549	Trametinib	2	72	sigmoid	sigmoid	BT549 trametinib 0 2 72	8	1.914	Inf	0.602	0.2	0.0685	0.581	0.837	0.995	1.05e-07	NA	Inf	0.654	0.822	0.0601	0.638	0.839	0.995	1.04e-07	NA
BT-549	Everolimus	3	72	sigmoid	flat	BT549 everolimus 0 3 72	8	1.587	59.5	0.533	0.425	1e-05	0.395	0.1	0.702	0.0264	NA	Inf	0.656	0.685	0.0	0.656	0.01	0.48	0.141	0.685
Hs 578T	Everolimus	1		sigmoid	sigmoid	Hs578T everolimus 1	8	2.030	1707115.0	0.626	0.318	0.00576	0.429	0.1	0.895	0.00116	NA	2.51e+21	0.657	0.704	0.00121	0.502	0.1	0.893	0.00124	NA
HCC70	CAL-101	1	72	sigmoid	sigmoid	HCC70 idelalisib 0 1 72	8	1.384	2.78	0.485	0.0894	0.883	0.424	1.65	0.972	2.11e-05	NA	Inf	0.662	0.941	0.846	0.626	1.66	0.97	2.79e-05	NA
HCC70	AS605240	1	72	sigmoid	sigmoid	HCC70 AS-605240 0 1 72	8	1.387	10.4	0.487	0.159	0.247	0.497	1.34	0.963	5.14e-05	NA	Inf	0.663	0.894	0.23	0.672	1.39	0.961	6.01e-05	NA
BT-549	Trametinib	1	72	sigmoid	sigmoid	BT549 trametinib 0 1 72	8	1.812	Inf	0.596	0.202	0.131	0.523	0.61	0.959	6.65e-05	NA	28.3	0.664	0.828	3.47	0.254	0.337	0.933	0.000305	NA
HCC38	Pictilisib	3	72	sigmoid	sigmoid	HCC38 pictilisib 0 3 72	8	1.420	3.12	0.499	0.129	2.45	0.0818	0.738	0.976	1.33e-05	NA	20.5	0.664	0.911	2.24	0.401	0.731	0.974	1.7e-05	NA
Hs 578T	MK2206	3		sigmoid	sigmoid	Hs578T MK-2206 3	8	2.883	Inf	0.737	0.0965	0.144	0.768	1.94	0.962	5.58e-05	NA	Inf	0.666	0.873	0.135	0.7	1.85	0.967	3.69e-05	NA
HCC38	Everolimus	3	72	sigmoid	sigmoid	HCC38 everolimus 0 3 72	8	1.437	5.11	0.511	0.429	0.000567	0.299	0.1	0.934	0.000284	NA	573000000.0	0.668	0.707	0.000349	0.53	0.1	0.932	0.000308	NA
HCC70	TGX221	3	72	sigmoid	sigmoid	HCC70 TGX-221 0 3 72	8	2.459	Inf	0.7	0.0886	0.338	0.675	1.11	0.971	2.48e-05	NA	Inf	0.671	0.9	0.295	0.648	1.13	0.966	3.94e-05	NA
BT-549	AZD-6482	2	72	sigmoid	sigmoid	BT549 AZD6482 0 2 72	8	1.973	9.15	0.635	0.112	120.0	-1.0	0.426	0.951	0.000115	NA	19.4	0.672	0.895	19.4	0.0	0.437	0.946	0.000154	NA
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
HCC38	PIK-93	1	72	sigmoid	sigmoid	HCC38 PIK-93 0 1 72	8	1.741	5.24	0.61	0.0782	24.5	-1.0	0.713	0.982	6.07e-06	NA	9.93	0.686	0.935	9.93	0.0	0.729	0.979	9.08e-06	NA
HCC38	Sirolimus	3	72	sigmoid	sigmoid	HCC38 rapamycin 0 3 72	8	1.420	86.3	0.535	0.403	0.000236	0.361	0.1	0.901	0.000982	NA	75575.0	0.687	0.727	0.000198	0.569	0.1	0.889	0.00136	NA
HCC70	Sirolimus	1	72	sigmoid	sigmoid	HCC70 rapamycin 0 1 72	8	1.416	37.6	0.533	0.397	0.00426	0.298	0.1	0.742	0.0172	NA	125000000.0	0.687	0.732	0.00186	0.541	0.1	0.74	0.0175	NA
HCC70	CAL-101	3	72	sigmoid	sigmoid	HCC70 idelalisib 0 3 72	8	2.510	Inf	0.724	0.0241	1.39	0.69	2.52	0.964	4.57e-05	NA	Inf	0.689	0.973	1.33	0.655	2.52	0.956	8.64e-05	NA
BT-549	AZD-6482	3	72	sigmoid	sigmoid	BT549 AZD6482 0 3 72	8	1.744	8.87	0.616	0.0979	2.2	0.324	0.749	0.993	2.93e-07	NA	115.0	0.69	0.918	1.91	0.476	0.744	0.993	4.19e-07	NA
BT-549	MK2206	1	72	sigmoid	sigmoid	BT549 MK-2206 0 1 72	8	1.811	Inf	0.632	0.189	0.103	0.58	0.8	0.911	0.000695	NA	Inf	0.692	0.839	0.101	0.642	0.73	0.911	0.000717	NA
HCC70	CAL-101	2	72	sigmoid	sigmoid	HCC70 idelalisib 0 2 72	8	1.738	Inf	0.62	0.0432	0.959	0.611	3.13	0.965	4.31e-05	NA	Inf	0.693	0.965	0.935	0.686	3.13	0.96	6.52e-05	NA
HCC70	Sirolimus	3	72	sigmoid	sigmoid	HCC70 rapamycin 0 3 72	8	2.548	310.0	0.732	0.227	0.000433	0.63	0.1	0.676	0.034	NA	22876.0	0.693	0.736	0.000237	0.58	0.1	0.659	0.0397	NA
Hs 578T	TGX221	1		sigmoid	sigmoid	Hs578T TGX-221 1	8	2.019	14.6	0.686	0.0936	23.9	-0.133	0.479	0.995	1.07e-07	NA	27.2	0.708	0.91	11.5	0.171	0.484	0.995	1.48e-07	NA
BT-20	XL147	3	72	flat	flat	BT20 pilaralisib 0 3 72	8	2.647	Inf	0.755	0.102	0.0	0.755	0.01	0.0679	0.81	0.885	Inf	0.708	0.871	0.0	0.708	0.01	0.0505	0.856	0.857
BT-549	PIK-93	2	72	sigmoid	sigmoid	BT549 PIK-93 0 2 72	8	1.983	7.03	0.687	0.0641	29.9	-1.0	0.759	0.956	8.81e-05	NA	10.4	0.713	0.939	10.4	0.0	0.788	0.949	0.000136	NA
HCC1806	Sirolimus	3	72	sigmoid	sigmoid	HCC1806 rapamycin 0 3 72	8	3.249	0.223	0.805	0.162	0.000183	0.746	0.1	0.663	0.0382	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)